

Special Issue

Clinical Management of Borderline Ovarian Tumors

Message from the Guest Editor

Borderline ovarian tumors (BOTs) are rare, but have shown an increase in the global incidence, biological behavior and prognosis between benign and malignant tumors. These tumors mostly occur in young women of reproductive age, and although they have a favorable prognosis, their management by consensus is essential to limit the risk of invasive recurrence. The global recurrence rate is estimated to be between 5% and 34%. Controversies surround the diagnostic criteria used for their assessment, and the optimal management to minimize their risk of recurrence, especially into malignant carcinoma. Fertility preservation is considered a cornerstone in the management of young patients. There is a similarity of histological features and survival between ovarian mucinous carcinoma (MC) with expansile invasion and ovarian mucinous borderline tumor (MBT). The prognostic outcome of MC with expansile invasion might mimic that of MBT. Recent studies have shown that ovarian borderline tumor treatment can be applied to MC treatment. There is disagreement in the current literature on several points concerning the safest and most effective way to manage women with these pathologies.

Guest Editor

Prof. Dr. Lobna Ouldamer

1. Department of Gynaecology, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, Tours, France
2. Unité INSERM (Nutrition, Growth and Cancer), U1069, Tours, France

Deadline for manuscript submissions

closed (30 October 2022)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/118325

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jcm)

[jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).